Status:
COMPLETED
Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding
Lead Sponsor:
AstraZeneca
Conditions:
Upper Gastrointestinal Bleeding
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Rus...
Eligibility Criteria
Inclusion
- Established diagnosis of acute upper gastrointestinal bleeding, confirmed by presence of hematemesis/ coffee ground vomiting, melena, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
- Written informed consent provided prior the start of participation in the study.
Exclusion
- Subjects who are unwilling or unable to provide informed consent.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01155401
Start Date
June 1 2010
End Date
June 1 2011
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Moscow, Russia